Evotec

Evotec EVO Stock

$1.46   -1.351350%
Add to favorites
Market Cap
$518.87M
LOW - HIGH [24H]
$1.46 - $1.51
VOLUME [24H]
$35.78K
P/E Ratio
0
Earnings per share
-$0.59
ISIN
US30050E1055
Price   Prediction

Evotec Price Chart

Sorry, that's all we've gotfor now...

Evotec (EVO) stock price today is 1.46 USD on Tech Market Large (-1.35% on the day). Updated .

Evotec EVO Financial and Trading Overview

Evotec stock price 1.46 USD
Previous Close 1.48 USD
Open 1.5 USD
Bid 1.07 USD x 200
Ask 1.9 USD x 200
Day's Range 1.49 - 1.51 USD
52 Week Range 1.33 - 3.87 USD
Volume 8K USD
Avg. Volume 107.99K USD
Market Cap 529.53M USD
Beta (5Y Monthly) 1.314
PE Ratio (TTM) N/A
EPS (TTM) -0.59 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 4.45 USD

EVO Valuation Measures

Enterprise Value 606.94M USD
Trailing P/E N/A
Forward P/E -7.8421054
PEG Ratio (5 yr expected) 1.42
Price/Sales (ttm) 0.7371761
Price/Book (mrq) 0.7347962
Enterprise Value/Revenue 0.845
Enterprise Value/EBITDA -10.153

Trading Information

Evotec Stock Price History

Beta (5Y Monthly) 1.314
52-Week Change -50.50%
S&P500 52-Week Change 10.51%
52 Week High 3.87 USD
52 Week Low 1.33 USD
50-Day Moving Average 1.58 USD
200-Day Moving Average 2.4 USD

EVO Share Statistics

Avg. Volume (3 month) 107.99K USD
Avg. Daily Volume (10-Days) 79.8K USD
Shares Outstanding 355.39M
Float 294.02M
Short Ratio 0.6
% Held by Insiders 0.15%
% Held by Institutions 0.39%
Shares Short 63.32K
Short % of Float 0.020%
Short % of Shares Outstanding 0.020%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 4:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -25.15%
Operating Margin (ttm) -17.96%
Gross Margin 10.26%
EBITDA Margin -8.32%

Management Effectiveness

Return on Assets (ttm) -4.92%
Return on Equity (ttm) -25.067%

Income Statement

Revenue (ttm) 718.32M USD
Revenue Per Share (ttm) 2.02 USD
Quarterly Revenue Growth (yoy) 0.59%
Gross Profit (ttm) 73.76M USD
EBITDA -59781000 USD
Net Income Avi to Common (ttm) -180704992 USD
Diluted EPS (ttm) -0.59
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 400.94M USD
Total Cash Per Share (mrq) 1.13 USD
Total Debt (mrq) 481.81M USD
Total Debt/Equity (mrq) 75.09 USD
Current Ratio (mrq) 2.322
Book Value Per Share (mrq) 2.0277731

Cash Flow Statement

Operating Cash Flow (ttm) -91386000 USD
Levered Free Cash Flow (ttm) 208.71M USD

Profile of Evotec

Country United States
State N/A
City Hamburg
Address Essener Bogen 7
ZIP 22419
Phone 49 40 560 81 0
Website https://www.evotec.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 4379

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Q&A For Evotec Stock

What is a current EVO stock price?

Evotec EVO stock price today per share is 1.46 USD.

How to purchase Evotec stock?

You can buy EVO shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Evotec?

The stock symbol or ticker of Evotec is EVO.

Which industry does the Evotec company belong to?

The Evotec industry is Drug Manufacturers - Specialty & Generic.

How many shares does Evotec have in circulation?

The max supply of Evotec shares is 355.39M.

What is Evotec Price to Earnings Ratio (PE Ratio)?

Evotec PE Ratio is now.

What was Evotec earnings per share over the trailing 12 months (TTM)?

Evotec EPS is -0.59 USD over the trailing 12 months.

Which sector does the Evotec company belong to?

The Evotec sector is Healthcare.

Evotec EVO included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24429.89 USD —
+0.42
6.99B USD — 24225.3 USD — 24538.78 USD — — 6.99B USD —
us US Tech Global Select Market Com NQGS US 12034.87 USD —
+0.42
— — 11933.12 USD — 12087.81 USD — — — —
us US Tech Health Care IXHC US 1324.44 USD —
-0.63
— — 1322.85 USD — 1342.46 USD — — — —
$2.17T
Total marketcap
$71.11B
Total volume
BTC 57.99%   •   ETH 9.91%
Dominance
Select currency